The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study.

Introduction: Cladribine tablets are an effective treatment for relapsing remitting multiple sclerosis (RRMS). However, almost half of the treated patients are not free of disease activity after two years. The aim of this study was to describe the changes that cladribine tablets effectuate in the gut and oral microbiota and the peripheral immunological profile between responders and non-responders.

Sacral Neuromodulation in Multiple Sclerosis: The NEMISIS Study.

Recent studies have shown promising sacral neuromodulation (SNM) results in neurogenic overactive bladder caused by multiple sclerosis. In the first half of 2025 we aim to start including patients in a multicentre, randomised controlled trial to test the hypothesis that SNM has a therapeutic benefit in this setting.

The effects of Calophyllum brasiliense leaves extract and isolated compound amentoflavone: implications in the resolution of inflammation.

Calophyllum brasiliense is employed in folk medicine as an analgesic and to treat inflammation. This study aimed to evaluate the anti-inflammatory effect of C. brasiliense leaves' methanol extract, fractions, and the isolated compound amentoflavone.

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.

Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated the impact of early therapeutic response on the 5-year prognosis of patients with relapsing-remitting MS (RRMS). We recruited patients from MSBase Registry covering the period between 1996 and 2022.

Explainable time-to-progression predictions in multiple sclerosis.

Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as this is a binary yes/no question, it cannot take individual disease severity into account. Therefore, in this work we propose to model the time to disease progression instead.